What Is the Limit of Detection in a Sequence Detection System?

What Is the Limit of Detection in a Sequence Detection System?

The limit of detection in a sequence detection system is the lowest amount of target DNA or RNA that the system can detect with reliable confidence. In simple words, it answers one nervous question: “How little genetic material can this test find before the result becomes uncertain?”

In qPCR, RT-qPCR, digital PCR, and other nucleic acid tests, this question is central because real samples are rarely perfect. A patient may have a low viral load. A food sample may carry only a few pathogen copies. A research sample may contain degraded DNA. At that edge, the system may detect the target in one run but miss it in another.

Most molecular testing work treats the limit of detection as the concentration detected in about 95% of repeated tests under defined conditions. The MIQE qPCR guidelines connect LOD with detection at reasonable certainty, with 95% probability commonly used.

What does limit of detection mean in a sequence detection system?

The limit of detection, often written as LOD or LoD, is the smallest target concentration that a sequence detection system can reliably call positive.

It does not mean the machine can measure that amount perfectly. It means the system can tell that the target is present often enough to trust the positive call. In molecular testing, that target may be viral RNA, bacterial DNA, a gene mutation, plasmid DNA, or another sequence of interest.

A sequence detection system usually includes more than the instrument. It includes sample collection, extraction, primers, probes, reagents, thermal cycling, fluorescence detection, software thresholds, and result interpretation.

LOD is not only about the detector. A sensitive optical system cannot rescue a poor extraction. A well-designed probe cannot fully fix an inhibited sample. The whole workflow shapes the final detection limit.

A common laboratory definition is simple: LOD is the lowest target concentration detected in at least 95% of replicate reactions. If a lab tests 20 replicates at a low concentration and at least 19 are positive, that level may support a 95% detection claim, depending on the validation design.

The FDA has treated LOD as a core sensitivity measure for qualitative PCR methods, especially in molecular diagnostic validation.

Is limit of detection the same as analytical sensitivity?

Yes, in many molecular testing conversations, LOD is used as the practical measure of analytical sensitivity.

Analytical sensitivity asks how small an amount of target the test can detect. LOD gives that idea a tested number. A SARS-CoV-2 RT-qPCR assay, for example, may report an LOD of 500 copies/mL, 1,000 copies/mL, or a certain number of genome copies per reaction.

Still, the wording can be confusing because “sensitivity” also has a clinical meaning. Clinical sensitivity tells how often a test correctly identifies real positive cases in a patient group. Analytical sensitivity tells how little target the assay can detect in controlled testing.

A test can have a very low analytical LOD but still miss some clinical cases if the sample is collected too early, stored poorly, extracted badly, or taken from the wrong site.

LOD is a lab performance measure. It is not a promise that every infected, exposed, or mutation-carrying sample will always test positive.

How is limit of detection usually reported?

LOD is usually reported as copies per reaction, copies per milliliter, genome copies per sample volume, international units per milliliter, or colony-forming-unit equivalents, depending on the test type.

In a qPCR assay, “copies per reaction” focuses on what enters the amplification tube. “Copies per mL” includes sample volume, extraction volume, elution volume, and how much extract enters PCR.

This difference can change how the number feels.

A test may detect 5 copies per reaction, but if the extraction step concentrates or dilutes the sample, the final sample-level LOD may look very different. In clinical and environmental testing, the process-level LOD is often more useful than the reaction-only LOD.

Researchers studying waterborne pathogen qPCR raised this exact issue: reported qPCR LODs often reflect only the PCR assay rather than the entire sample process, and a 95% LOD should account for the full detection process.

Two LOD numbers can both be true but not equal. One may describe the amplification chemistry. The other may describe the full workflow from sample to final result.

Why does the 95% detection rule matter?

The 95% rule is important because detection near the lower edge is partly random.

When very few target molecules are present, one reaction tube may receive a copy while another tube receives none. This is not always a machine failure. It is sampling math. At very low copy numbers, molecules do not divide evenly across replicate wells.

One major review on Cq interpretation defines the LOD as the average number of target copies that shows amplification in at least 95% of reactions. It also notes that Poisson sampling can place a natural limit near a few copies per reaction when single-copy amplification is possible.

A single target molecule may be detected under ideal conditions. But a reliable test cannot depend on luck. It needs enough target present so repeat testing finds it most of the time.

The 95% rule separates “the system might see it” from “the system can be trusted to see it.”

What is the difference between LOD, LoB, and LoQ?

LOD means the lowest level that can be reliably detected. LoB means the highest signal expected from a blank sample. It means the lowest level that can be measured with acceptable precision.

These terms sound similar, but they answer different questions.

The limit of blank, or LoB, asks: “How much signal can appear when no real target is present?” Blank samples may still produce background fluorescence, primer-dimer signals, nonspecific noise, or software artifacts.

The limit of detection asks: “At what low concentration can we reliably tell target signal from blank noise?”

The limit of quantification, or LoQ, asks: “At what concentration can we measure the amount with acceptable accuracy and precision?”

A clinical chemistry reference defines LoD as the lowest analyte concentration likely to be reliably distinguished from the blank, and gives the common relationship where LoD is derived from LoB plus variation in low-concentration samples.

In sequence detection, this distinction is significant.

A qPCR assay may detect a weak positive at 38 cycles, but that does not mean the assay can measure the starting quantity accurately. Detection can happen below the level where quantification is trustworthy.

Why can a sequence detection system detect but not quantify a target?

A system can detect a tiny amount of DNA or RNA because amplification makes the target visible, but quantifying that tiny amount is harder because small copy numbers behave unpredictably.

At low concentrations, small pipetting differences, extraction variation, inhibitors, and random molecular distribution can move the Cq value by several cycles. A reaction may be positive, but the measured quantity may not be precise enough for dose, viral load, copy number, or fold-change reporting.

Near the LOD, the same sample may not give the same Cq each time. That makes exact quantification risky.

LoQ sits above LOD because LOD is about presence and LoQ is about reliable amount.

A good report should not treat every weak positive as a clean number. In low-copy detections, wording such as “detected below quantifiable range” may be more honest than a firm concentration.

How do labs determine the limit of detection?

Labs determine LOD by testing low concentrations of the target many times and finding the lowest level that produces positive results with the required detection rate.

The work usually starts with a known reference material. This may be synthetic DNA, RNA transcript, plasmid, cultured organism, inactivated virus, or quantified clinical material. The lab makes a dilution series and tests several replicates at each level.

A simple LOD study may begin with broad dilutions to find the approximate range. Then the lab tests tighter concentrations around the expected detection edge.

In molecular diagnostic work, FDA recommendations for COVID-19 molecular tests included spiking quantified inactivated virus into real negative clinical matrix, such as nasal or nasopharyngeal swabs, sputum, or bronchoalveolar lavage fluid. That approach is important because clean buffer often makes a test look more sensitive than real specimens do.

The most useful LOD study should answer three things at once:

Question	Why it matters
What target level was tested?	The LOD must be tied to a real concentration.
How many replicates were positive?	Reliability depends on repeated detection.
What sample matrix was used?	Buffer, plasma, swab media, stool, and wastewater behave differently.

A strong LOD claim comes from repeated testing in the same type of sample the system will face in real use.

What does “copies per reaction” mean?

Copies per reaction means the number of target DNA or RNA molecules expected inside the amplification tube.

This number is useful because PCR happens inside the reaction well. If a test detects 10 copies per reaction, the assay chemistry and instrument can usually detect around 10 target molecules in the tested reaction volume.

But this number does not always tell the full story.

Suppose the original sample is 1 mL. The lab extracts nucleic acid, elutes into 100 µL, and adds 5 µL of extract into the PCR reaction. The reaction contains only a fraction of the original sample. Losses during extraction and uneven target distribution can raise the true sample-level LOD.

A test with a low copies-per-reaction LOD may still miss weak real-world samples.

Copies per reaction is a helpful number, but it is not the whole patient, food, environmental, or research sample story.

What does “copies per mL” mean?

Copies per mL means the target concentration in the original sample volume, not just in the PCR tube.

This unit is common in viral load testing and clinical diagnostics. It helps clinicians and lab teams understand how much target must be present in the specimen for the system to detect it.

One triplex RT-qPCR assay developed for SARS-CoV-2 had an LOD of 1,000 copies/mL. In that study, the assay also showed 97.7% sensitivity and 100% specificity against the comparison method in the tested sample set.

Copies per mL can be easier to understand than copies per reaction because it connects to the specimen. But it depends heavily on extraction volume, elution volume, input volume, and sample preparation.

Two assays may both claim 10 copies per reaction but have different copies-per-mL LODs because their extraction and input volumes differ.

What factors affect the limit of detection?

LOD is affected by sample quality, extraction efficiency, target stability, primer and probe design, amplification chemistry, instrument performance, background noise, and analysis thresholds.

A sequence detection system is only as strong as its weakest step. The target must survive collection, move through extraction, bind correctly to primers and probes, amplify efficiently, and cross the detection threshold before the result can be called positive.

Sample matrix has a large role. Blood, stool, soil, wastewater, tissue, saliva, and respiratory swabs can carry inhibitors. These substances may slow amplification or suppress it completely.

Extraction efficiency also matters. If extraction loses half the target, the assay receives less template. If elution is too dilute, the target may fall below the detection edge.

Primer and probe design shape specificity and signal strength. A mismatch near the primer’s 3′ end can reduce amplification. Probe mismatches may weaken fluorescence. Secondary structures can block binding. Multiplex assays may also create competition between targets.

Instrument optics and software thresholds add another layer. Weak fluorescence must stand out from baseline noise. A threshold set too low can increase false positives. A threshold set too high can miss weak true positives.

LOD is a system property, not a single reagent property.

How do primers and probes affect LOD?

Primers and probes affect LOD because they decide how efficiently the target sequence is copied and detected.

Well-designed primers bind the right target, avoid strong dimers, and amplify with good efficiency. Poor primers waste reagents, form nonspecific products, or fail when the target carries mutations.

In probe-based systems such as TaqMan assays, the probe adds specificity and fluorescent signal. A strong probe can make low-copy detection cleaner. A weak probe can make the same target harder to detect, even when amplification occurs.

Mutations in the target region can also raise the LOD. If a primer or probe no longer binds well, the assay may need more starting material to produce a positive signal. In pathogen testing, this is one reason labs track sequence variation.

LOD is not permanent. It can change when the target sequence changes, the sample type changes, or the assay design changes.

How does sample extraction affect LOD?

Sample extraction affects LOD because only the nucleic acid that survives extraction can be detected.

A sample may contain the target, but if extraction is inefficient, the final PCR tube may receive too few copies. Extraction losses are especially costly near the detection edge because there are not many molecules to spare.

RNA targets face an additional challenge. RNases, heat, freeze-thaw cycles, and poor storage can break RNA before testing. Once the target is damaged, even a highly sensitive sequence detection system cannot detect what is no longer intact.

Extraction can also carry inhibitors into the final reaction. These inhibitors may delay Cq values or cause false negatives. Internal controls are often used to catch this problem.

A reaction-only LOD may look excellent, but a full-process LOD may be higher once extraction is included. In real samples, the full-process value is usually the more honest number.

How does sample volume affect the detection limit?

Larger sample volume can improve detection if the workflow captures and concentrates the target well, but more volume can also bring more inhibitors.

More starting material may contain more copies of the target, which helps when the target is rare. But larger or dirtier samples can overload extraction columns, reduce purity, or carry compounds that disturb PCR.

Environmental testing shows this clearly. Wastewater, soil, and food samples may need concentration steps before extraction. But each step can lose material. The final LOD depends on recovery across the whole process, not just the PCR chemistry.

In clinical swabs, collection quality often counts as much as volume. A poorly collected swab may contain little human or pathogen nucleic acid. In that case, even a low LOD cannot make the sample representative.

The best LOD is not always achieved by adding more sample. It is achieved by getting enough clean target into the reaction.

How do Cq or Ct values relate to LOD?

Cq or Ct values relate to LOD because weak positive samples cross the fluorescence threshold late in the run.

A low Cq usually means there was more target at the start. A high Cq usually means there was less target. Near the LOD, Cq values often appear late and vary more between replicates.

But Cq is not the same as LOD.

A single late Cq does not prove the assay’s detection limit. It may be a true low-copy target, contamination, primer-dimer signal, or baseline artifact. The LOD must be tested across repeated low-level samples.

A result at Cq 39 may be real, but it sits close to the zone where repeatability becomes weaker. Labs often use cutoff rules, replicate testing, melt curves, probe specificity, controls, and clinical context to decide how to report such results.

LOD gives the boundary. Cq gives the run-level signal.

What is a good limit of detection for qPCR?

A good qPCR LOD depends on the target, sample type, assay purpose, and reporting unit. Many strong assays can detect low copy numbers per reaction, but real-world sample-level LODs are often higher.

In highly controlled qPCR reactions with purified template, detection near a few copies per reaction may be possible. The qPCR Cq review referenced above connects ideal single-copy detection with a theoretical lower edge near three copies per reaction because of Poisson variation.

In clinical, food, forensic, agricultural, and environmental workflows, the practical LOD may be much higher. Extraction loss, inhibitors, transport media, sample storage, and target degradation all add distance between theory and reality.

A “good” LOD is not one universal number. It is a number that fits the decision being made.

A research assay for abundant gene expression may not need an ultra-low LOD. A residual disease assay, early infection test, or contamination screen may need far greater low-copy reliability.

The better question is not “Is the LOD low?” The better question is “Is the LOD low enough for the sample type and decision?”

What is a good LOD for digital PCR?

A good digital PCR LOD also depends on target, partition number, input amount, and sample preparation, but dPCR can be strong at low-copy detection because it partitions the sample into many small reactions.

Digital PCR does not rely on a standard curve in the same way qPCR does. It counts positive and negative partitions and applies Poisson statistics. This can help with rare target measurement, copy number variation, low-level mutations, and samples that are hard to quantify by qPCR.

Still, dPCR is not magic. If the target never enters the partitioned reaction, it cannot be detected. Extraction loss, sample input, inhibitors, and partition volume still affect the final LOD.

In some comparisons, dPCR has shown lower process LOD than RT-qPCR for specific wastewater SARS-CoV-2 targets. One study found that RT-dPCR for the CDC N1 target had lower 50% and 95% process LOD estimates than several RT-qPCR assays in that workflow.

The full method must always be tested; no platform wins by assumption.

Why do different sequence detection systems report different LODs?

Different systems report different LODs because they use different sample types, extraction methods, target regions, chemistries, instruments, thresholds, replicate numbers, and statistical methods.

Even the same assay can produce different LODs in different labs. Pipetting technique, reagent lots, calibration, extraction platform, and sample matrix can all move the number.

LOD values should always be read with context. A claim of “10 copies” sounds impressive, but the reader needs to ask:

• Was that copies per reaction or copies per mL?
• Was the target diluted in water, buffer, negative clinical matrix, or real sample material?
• How many replicates were tested?
• Was the LOD confirmed at 95% detection?
• Were extraction and sample prep included?
• Was the assay singleplex or multiplex?

A lower number is not always a better comparison if the study design is different.

Why does multiplex testing sometimes raise the LOD?

Multiplex testing can raise the LOD because several primer and probe sets share the same reaction space.

Multiplex assays are useful because they can detect multiple targets in one tube. A respiratory panel may test for several viruses. A pathogen assay may include two target genes and an internal control. A genotyping assay may test wild-type and mutant sequences together.

But multiplexing can create competition. One abundant target may amplify strongly while a rare target struggles. Primer interactions can create dimers. Fluorescent channels can overlap. Reagent balance becomes more sensitive.

Good assay design can reduce these problems, but every added target increases the burden of validation. A multiplex assay should have its LOD checked for each target, not just the panel as a whole.

The low-copy target is often where weakness appears first.

How do inhibitors affect the limit of detection?

Inhibitors raise the LOD because they make amplification less efficient or stop it completely.

PCR inhibitors can come from hemoglobin, heparin, bile salts, humic acids, food compounds, ethanol carryover, extraction reagents, and many other sources. Their effect may be subtle. A sample may still amplify, but several cycles later than expected.

Near the LOD, that delay can be enough to change a result from positive to negative.

Internal amplification controls help identify inhibition. If the internal control is delayed or absent, the lab may need dilution, re-extraction, cleanup, or a new sample.

LOD should be tested in the intended matrix. An assay diluted in clean water may look sensitive, while the same assay in stool or wastewater may need far more target to reach the same detection rate.

How does contamination affect LOD interpretation?

Contamination can make an assay appear to have a lower LOD than it truly has.

If low-level target contaminates reagents, tubes, plates, pipettes, or workspaces, blank samples may turn positive. That creates a false picture of sensitivity. The system seems to detect tiny amounts, but some of the signal may not come from the intended sample.

At high target levels, contamination may be less visible. Near the LOD, even a few stray molecules can change the result.

Controls are the guardrails. No-template controls, extraction blanks, negative matrix controls, and separate pre-PCR and post-PCR areas help protect the LOD study.

A clean LOD validation should show low-level positives where target is added and clean negatives where no target is present. Without that, the LOD claim becomes shaky.

How is LOD verified in a clinical lab?

A clinical lab verifies LOD by testing samples near the manufacturer’s claimed detection limit and checking whether the expected positive rate is achieved.

Many molecular tests do not require the lab to fully re-create the manufacturer’s entire validation from scratch. Instead, the lab verifies that the claimed LOD works in its own hands, with its own staff, instruments, extraction system, and sample workflow.

Published work on verifying claimed LOD in molecular diagnostics outlines the CLSI EP17-A2 approach, where a claimed LOD is verified by testing a sample at that concentration and checking whether the confidence interval for the observed positive rate contains the expected 95% detection rate.

Verification protects patients, researchers, and downstream decisions from assumptions.

What role do standards and guidelines play in LOD?

Standards and guidelines give labs a shared way to define, test, and report detection limits.

Without shared rules, one lab might define LOD as any level that gives one positive result, while another lab requires 95% detection across many replicates. Those two numbers would not mean the same thing.

Reporting quality expectations for qPCR studies were strengthened by requiring researchers to share sufficient experimental detail for readers to judge reliability. This framework defines the minimum information needed to evaluate qPCR experiments and promote consistency between laboratories.

CLSI EP17 is widely used for detection capability concepts such as LoB, LoD, and LoQ. The CLSI organization develops consensus standards and guidelines for clinical laboratory testing.

Guidelines do not remove all judgment. They make the judgment clearer.

Can LOD change after a test is already validated?

Yes, LOD can change after validation if the workflow, reagents, software, instrument, sample type, or target sequence changes.

Even a small change can have consequences. A new extraction kit may recover less RNA. A new swab medium may introduce inhibitors. A software update may adjust baseline correction. A new primer lot may perform differently. A pathogen variant may develop a mismatch in the primer or probe binding site.

Labs often need change-control rules because of this. If the change could affect detection at low copy numbers, LOD may need partial or full re-checking.

A test that worked well last year may still work today, but the lab should not assume that without monitoring controls, failures, variant data, and quality trends.

LOD is not a trophy number. It is a living performance claim.

How should weak positives near the LOD be interpreted?

Weak positives near the LOD should be interpreted carefully because repeatability is lower at very low target levels.

A weak positive may mean true low-level target. It may also reflect contamination, nonspecific signal, degraded sample, or a borderline threshold call. The result must be read with controls, replicate behavior, amplification curve shape, target biology, and sample history.

In clinical testing, a weak positive can still have significance. Early infection, late infection, treated infection, or low pathogen burden may all produce weak signals. In research, weak positives may need repeat testing or confirmation with another target.

The mistake is treating every weak signal as equally firm.

A clean, repeated, target-specific weak positive is different from a single late curve in a messy run. LOD helps labs decide where that confidence begins to fade.

What is the difference between assay LOD and process LOD?

Assay LOD refers mainly to the amplification and detection step. Process LOD includes the full workflow from sample preparation through final result.

Assay LOD may be tested by adding known target directly into the PCR reaction or extracted nucleic acid. Process LOD may begin by adding target into the original sample matrix before extraction.

Process LOD is usually more realistic because it includes losses and interference from collection, concentration, extraction, purification, elution, and amplification.

In environmental and clinical work, process LOD often counts more. It answers the real question: “How little target in the original sample can the whole system detect?”

A strong assay LOD can still fail the real sample if preparation is weak.

How can labs lower the limit of detection?

Labs can lower LOD by improving sample recovery, reducing inhibitors, increasing clean template input, refining primer and probe design, improving amplification efficiency, and setting well-tested analysis thresholds.

The first step is usually not the instrument. It is the workflow.

Better collection can place more target into the tube. Better extraction can recover more nucleic acid. Better cleanup can reduce inhibitors. Better primer and probe design can increase amplification efficiency. Better controls can reveal where signal is being lost.

Labs may also increase replicate testing. If the target is rare, testing more than one reaction from the same extract can improve the chance of detection. This is not the same as making the assay chemically more sensitive, but it can improve sample-level detection.

Concentration steps may help with low-burden samples, especially in environmental testing. But concentration must be checked for recovery, because adding steps can also add losses.

Lowering LOD is not about chasing the smallest number on paper. It is about making the low-level result more dependable.

What mistakes make LOD claims unreliable?

LOD claims become unreliable when they are based on too few replicates, clean buffer instead of real matrix, unclear units, missing extraction steps, weak controls, or a detection rate below the stated confidence level.

A common mistake is reporting the lowest dilution that produced one positive result. That is not a strong LOD. It only proves detection happened once.

Another mistake is mixing up copies per reaction and copies per sample. A number may sound small because it ignores extraction dilution or sample input.

Some reports also fail to separate detection from quantification. A late weak signal may be detectable but not measurable with useful precision.

The best LOD claims are transparent. They identify the target material, dilution method, matrix, replicate count, positivity rule, instrument, extraction method, and statistical basis.

Readers should never have to guess what the LOD number means.

How does LOD affect false negatives?

LOD affects false negatives because samples below or near the detection limit may not test positive every time.

A false negative can happen when the target is present but below the system’s reliable detection range. It can also happen when collection misses the target, extraction loses it, inhibitors block amplification, or target degradation occurs.

Near the LOD, the test is working at the edge of probability. One replicate may receive enough target. Another may not. Very low target levels produce inconsistent results.

In patient testing, a negative result does not always rule out disease when exposure timing, symptoms, or sampling quality suggest otherwise. In research, low-copy findings need careful replication.

LOD sets the lower confidence boundary of the system.

How does LOD affect false positives?

LOD does not directly measure false positives, but low-level detection studies can reveal false-positive risks through blank and negative controls.

When an assay is tuned to catch tiny amounts of target, contamination control becomes more demanding. A few molecules can create a positive signal. This is especially true for amplified products from previous PCR runs.

LoB is the related concept here. If blank samples produce background signal, the lab must know how high that blank signal can go before calling a true positive.

A very low LOD is useful only when specificity and contamination control are strong. Otherwise, the assay may become sensitive to noise.

Sensitivity without clean negative controls is not trustworthy.

How should LOD be written in a test report or method section?

LOD should be written with the unit, detection probability, sample matrix, replicate design, and workflow scope.

A clear statement might look like this:

“The assay LOD was 10 copies per reaction, defined as the lowest concentration detected in at least 95% of 20 replicates using purified synthetic RNA.”

A stronger process-level statement might look like this:

“The process LOD was 1,000 copies/mL, defined as the lowest concentration detected in at least 95% of replicates after spiking quantified inactivated virus into negative nasopharyngeal swab matrix and processing through extraction and RT-qPCR.”

The second statement tells the reader far more. It shows the matrix, workflow, unit, and confidence rule.

A vague statement like “the assay is highly sensitive” gives almost no usable information.

What should buyers or lab managers ask before choosing a sequence detection system?

Buyers and lab managers should ask whether the LOD was tested in the same sample type, workflow, and target range they plan to use.

The brochure number is only the start. A lab should ask what the number means in practice.

Question	What it reveals
Is the LOD reported per reaction or per original sample volume?	Whether the number reflects the tube or the specimen.
Was extraction included?	Whether the full workflow was tested.
What matrix was used?	Whether the claim matches real samples.
How many replicates were tested?	Whether the detection rate is reliable.
Is the LOD target-specific in multiplex mode?	Whether every target performs well.
What controls are included?	Whether inhibition and contamination are monitored.
What happens near the cutoff?	Whether weak positives are handled carefully.

A system with a slightly higher but well-proven process LOD may be more useful than one with a strong reaction-only number tested under ideal conditions.

What is the practical meaning of LOD for real samples?

The practical meaning of LOD is simple: it tells you when a negative result starts becoming less certain because the target may be too scarce to detect.

In clinical settings, this can affect early infection testing or low viral load interpretation. In food safety labs, it can affect pathogen screening. In research, it can affect rare transcript detection. In biomanufacturing, it can affect contamination control.

LOD also tells teams when they should repeat, confirm, concentrate, or collect a better sample.

It should never be treated as a decorative validation number. It is one of the main boundaries between confidence and uncertainty.

A lower detection limit only matters when the whole system can support it

The limit of detection in a sequence detection system is the lowest amount of target DNA or RNA that can be found with reliable confidence, often using a 95% detection rule. But the real value of LOD depends on how it was tested.

A number measured in clean buffer does not tell the same story as a number measured in real sample matrix. A reaction-only LOD does not carry the same weight as a full-process LOD. A weak late signal does not always mean the system can quantify the target.

The best labs treat LOD as a practical safety line. They use it to design better assays, set honest cutoffs, read weak positives carefully, and explain negative results with the right amount of caution.

When a sequence detection system can detect low-copy targets and prove that performance in real samples, the result is more than a sensitive test. It becomes a result people can trust when the answer sits close to the edge.